Scholarlink

Background <p>Spanlastics are elastic nanovesicles designed to improve drug solubility, stability, and penetration across ocular barriers, which makes them ideal for delivering linezolid to the eye. The paper discusses in detail linezolid ocular delivery and its therapeutic efficiencies.</p> Main body <p>Treatment conditions that are associated with optics and, in particular, with antibiotic-resistant bacteria represent a major reason for therapeutic limitations that develop through limited and conventional delivery systems of drugs. One synthetic antibiotic like linezolid, has been widely used for excellent efficacy against infections caused by methicillin-resistant <i>Staphylococcus aureus</i>, among many gram-positive bacteria, and hence, there is an opportunity for its use as an ocular agent of therapy. However, poor ocular bioavailability, limited penetration to deeper eye tissues, and the requirement for frequent administrations have often been associated with medical efficacy. Novel tactics for transferring pharmaceuticals, such as spanlastics, have emerged as an encouraging approach to overcome some of the difficulties. This article examines some of the critical factors that decide the performance of spanlastics formulations, for example, the ability to enhance bioavailability by improving the uptake of the drug within the eye's front and back regions. Further, the sustained release properties of spanlastics are discussed, which may significantly reduce the dosage periodicity, thereby, compliance from the patients is improved. The review also discusses targeted delivery of the drug through surface modification or conjugation of targeting ligands such that linezolid is delivered with improved accuracy to the site of infection, thus improving benefits of therapy while minimizing widespread negative impacts.</p> Conclusion <p>In this review<b>,</b> the possibility of linezolid-loaded spanlastics in treating the increasing issue of antibiotic resistance in ocular infections is presented. Advanced formulations with increased stability, targeted delivery, and improved patient compliance can be the future prospects of this novel drug delivery system, which can be a promising solution that allows for overall successful management regarding numerous types of sight ailments.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Spanlastics ocular delivery: a comprehensive review of formulation and therapeutic potential

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月19日

查看全文
  • Saruma Sahin,
  • Swapnaneel Sarma,
  • Anisa Das,
  • Bitopan Baishya,
  • Amit Kumar Das,
  • Manoj Kumar Deka

摘要

Background

Spanlastics are elastic nanovesicles designed to improve drug solubility, stability, and penetration across ocular barriers, which makes them ideal for delivering linezolid to the eye. The paper discusses in detail linezolid ocular delivery and its therapeutic efficiencies.

Main body

Treatment conditions that are associated with optics and, in particular, with antibiotic-resistant bacteria represent a major reason for therapeutic limitations that develop through limited and conventional delivery systems of drugs. One synthetic antibiotic like linezolid, has been widely used for excellent efficacy against infections caused by methicillin-resistant Staphylococcus aureus, among many gram-positive bacteria, and hence, there is an opportunity for its use as an ocular agent of therapy. However, poor ocular bioavailability, limited penetration to deeper eye tissues, and the requirement for frequent administrations have often been associated with medical efficacy. Novel tactics for transferring pharmaceuticals, such as spanlastics, have emerged as an encouraging approach to overcome some of the difficulties. This article examines some of the critical factors that decide the performance of spanlastics formulations, for example, the ability to enhance bioavailability by improving the uptake of the drug within the eye's front and back regions. Further, the sustained release properties of spanlastics are discussed, which may significantly reduce the dosage periodicity, thereby, compliance from the patients is improved. The review also discusses targeted delivery of the drug through surface modification or conjugation of targeting ligands such that linezolid is delivered with improved accuracy to the site of infection, thus improving benefits of therapy while minimizing widespread negative impacts.

Conclusion

In this review, the possibility of linezolid-loaded spanlastics in treating the increasing issue of antibiotic resistance in ocular infections is presented. Advanced formulations with increased stability, targeted delivery, and improved patient compliance can be the future prospects of this novel drug delivery system, which can be a promising solution that allows for overall successful management regarding numerous types of sight ailments.